Why the study?
Do blood biomarkers predict all-cause, cardiac, or cancer death in patients after transient ischemic attack or minor ischemic stroke?
Population
929 consecutive patients with transient ischemic attack or minor ischemic stroke from a population-based study
Design
Cohort
Follow-up
5560 patient-years
Authors
Loading...
These biomarkers may refine post-TIA mortality risk stratification; hypothesis-generating and requires prospective validation before clinical use.
Do blood biomarkers predict all-cause, cardiac, or cancer death in patients after transient ischemic attack or minor ischemic stroke?
NT-proBNP and heart-type fatty-acid-binding protein independently predict vascular and cancer death, respectively, after TIA or minor stroke, potentially aiding in patient selection for occult disease screening.
Greisenegger et al. (2015) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: